Tirzepatide achieves an average reduction of 22.5%, while retatrutide shows early indications of up to 24.2%
They are not intended to represent clinical evidence in humans, and AOD-9604 has not been approved by the FDA, EMA, or any other regulatory authority for any indication
The SURPASS-1 trial investigated the efficacy and safety of the three doses of 5, 10, or 15 mg tirzepatide in drug-nave patients with T2D who were not sufficiently controlled with a lifestyle intervention with diet and exercise versus placebo (70)
These are the 18 common mistakes to avoid while using GLP-1 medications for weight loss: Mistakes That Can Cause Side Effects or Discomfort Eating Large Meals GLP-1 medications slow digestion, it is one of the benefits of these medications for weight loss
Lets focus on improving our own health literacy so we can feel better, function better, and live longer.